Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
CEO: Joseph Edward Tucker. Company website
Enveric Biosciences, Inc. (ENVB) trades at $3.88, down 24.81% on the day, as of Sep 20, 2026 14:59 UTC.
Enveric Biosciences, Inc. has a market capitalisation of $2.32M, calculated from the live ENVB share price and shares outstanding.
ENVB has no meaningful price-to-earnings ratio: Enveric Biosciences, Inc. lost $14,610.70 per share over the last twelve months, and a P/E is only defined on positive earnings.
Enveric Biosciences, Inc. generated revenue of $0.00 over the trailing twelve months.
ENVB has traded between $1.71 and $7.88 over the past 52 weeks, and the last price is 50.8% below that high.
Yes. Enveric Biosciences, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
Wall Street analysts rate ENVB Buy.
Enveric Biosciences, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Joseph Edward Tucker is the chief executive of Enveric Biosciences, Inc., which employs 5 people.
QFI Terminal shows ENVB with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ENVB in Terminal See plans